Acute Myelomonocytic Leukemia Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Acute Myelomonocytic Leukemia. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Acute Myelomonocytic Leukemia receives a directional strategic score of 65/100, combining unmet need (80/100), competitive intensity (77/100, where higher means more competition) and market attractiveness (78/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A pediatric acute myeloid leukemia involving both myeloid and monocytoid precursors. At least 20% of non-erythroid cells are of monocytic origin.

The reproducible entity is Patsnap disease ID 3a04666e468a4de4b78ffd6f20c91fa2 with MeSH identifier D015479. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Epidemiology of myasthenia gravis in France: Incidence, prevalence, and comorbidities based on national healthcare insurance claims data Epidemiology of myasthenia gravis in France:Incidence, prevalence, and comorbidities based onnational healthcare insurance claims data

Using EGB data, this study is the first to provide insight into the epidemiology of MG in France. These data highlight a much higher incidence and prevalence of the disease than generally reported, with a very high prevalence among men over 70. In addition, there is a clear statistical association between MG and certain comorbidities, notably the existence of diseases that affect the thymus, as well as an increased prevalence of cancer. Our results appear to modify the epidemiological know- ledge of MG, challenging previous studies conducted in Western countries, especially in Europe. In particular, we found an incidence of MG of over 50 per million person-years, far above the highest estimation in the literature of 30 per million person-years [7]. Focusing on the last years of the study period, the prevalence was above 500 per million people (reaching a peak of 586 patients per million people), whereas the literature suggests a range of 15 to 320 per million. These significant differences can be attributed to several factors, although they cannot be verified by our study. The methodo- logy employed in previous studies relied on retrospective analyses (study of medical records or hospital database analyses), which were probably not exhaustive. Studies using the EGB are undoubtedly much more effective for identifying patients with specific diseases, and the use of our algorithm likely enabled us to be almost exhaustive in the identification of MG patients. Furthermore, the EGB data we used are more recent (2008–2018) than most of the literature data and part of the increase in in

Review the epidemiology source

Epidemiology evidence 2: Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide

6. Seasonal variation Three studies [Tohoku region (Japan), Verona (Italy), and Quebec (Canada)] reported an autumn-winter predominance for the onset of MOGAD (23, 33, 50). However, a joint study from Germany and the Kanto region in Japan did not find such a trend (51). That study reported the lowest incidence of MOGAD onset during autumn in both the German and Kanto cohorts. A UK study did not observe seasonal variation in MOGAD onset either (52). More studies are needed to further clarify this aspect. 7. Conclusion We reviewed the currently available data from population- based MOGAD studies conducted around the world. The prevalence of MOGAD is approximately 1.3–2.5/100,000, and the annual incidence is approximately 3.4–4.8 per million. As disease awareness increases, and with the ease of availability of MOG antibody assays, the prevalence is expected to rise in the future. Moreover, through the application of the international diagnostic criteria of MOGAD (12), the epidemiological data are expected to be more accurate. Among White people, the prevalence of MOGAD appears to be slightly higher than that of AQP4+ NMOSD. Conversely, in populations or regions where the prevalence of AQP4+ NMOSD is higher (such as in Japan), MOGAD appears comparatively less common. So far, there has been no obvious racial preponderance observed in MOGAD, though the slight increase in prevalence among South Asians requires further investigation. The role of precedent infection observed in a proportion of MOGAD cases is also worthy of further research. More population-based studies in different

Review the epidemiology source

Epidemiology evidence 3: Incidence and prevalence of autoimmune diseases in China: A systematic review and meta-analysis of epidemiological studies

Due to the difference in the magnitude of estimates between condi­ tions, we grouped conditions into “low prevalence” (CD, UC, IBD, MS, T1D and SLE) and “high prevalence” (RA, GD and AT) groups, based on whether the pooled estimates were lower than 100 per 100,000 persons, or greater, respectively. For CD and UC, the fixed-effects pooled esti­ mates were 3.73 (95% CI 3.68–3.78), 16.11 (15.93–16.29) and random- effects estimates were 3.40 (0.50–22.92) and 12.59 (4.46–35.55) per 100,000 persons, respectively, based on four studies covering Taiwan, Hong Kong and mainland China (Fig. 3) [26,27,37,38]. Several other studies were identified but were excluded due to partial overlap or insufficient data (Supplementary Table 3). The Hong Kong studies, [27] which used active case finding had higher prevalence than the Taiwan[26,39] and mainland China studies, [37,38] which did not. For MS (7 estimates; 7 studies) the pooled estimates were 4.08 (3.95–4.21) and 2.45 (1.40–4.29) per 100,000 persons in the fixed-effects and random-effects models, respectively [33,40–45]. One prevalence esti­ mate was identified for T1D of 47.90 (95% CI 47.01–48.79) per 100,000 persons in Taiwan [46]. For SLE (6 estimates; 6 studies) the pooled es­ timates were 93.44 (92.27–94.63) and 60.30 (41.28–88.08) per 100,000 persons in the fixed-effects and random-effects models, respectively [47–52]. Except for SLE, where two of the studies were based on survey data, all other estimates in the “low prevalence” group were based on Fig. 2. Incidence of autoimmune diseases.

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Acute Myelomonocytic Leukemia, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Acute Myelomonocytic Leukemia thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: p53

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17189187, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:38653238, PubMed:9840937). Negatively regulates cell division by controlling expression of a set of genes required for this process (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:9840937). One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression (PubMed:12524540, PubMed:17189187). Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 (PubMed:12524540). However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP (PubMed:12524540). In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).

The mechanism anchor is TP53. It is a pathway hypothesis, not a claim that every Acute Myelomonocytic Leukemia patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 91 registered studies. Recent sampled records include:

• NCT06756152 — Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis; Recruiting; Phase 2/3; sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology; enrollment 50.
• CTRI/2024/09/073306 — Bioequivalence (BE) study of Azacitidine tablets 300 mg with ONUREG (Azacitidine) tablets 300 mg in patients with Acute Myeloid Leukemia.; Closed to Recruitment of Participants; Not Applicable; sponsor Qilu Pharmaceutical Co., Ltd., CBCC Global Research LLP; enrollment 48.
• NCT05515029 — Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis; Active, not recruiting; Phase 3; sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology; enrollment 56.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate TP53 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Acute Myelomonocytic Leukemia merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if TP53 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Acute Myelomonocytic Leukemia is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.